Allergy TherapeuticsLSE:AGY -11.27% Current Ratio is 1.13 as of Dec. 2025, which is 58% below its 10-year median of 2.72. The stock has 7 warning signs investors should review. Among 997 Drug Manufacturers companies, Allergy Therapeutics ranks worse than 78.44% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Allergy Therapeutics's current ratio for the quarter that ended in Dec. 2025 was 1.13.
Allergy Therapeutics has a current ratio of 1.13. It generally indicates good short-term financial strength.
The historical rank and industry rank for Allergy Therapeutics's Current Ratio or its related term are showing as below:
LSE:AGY'
s Current Ratio Range Over the Past 10 Years
Min: 1.13 Med: 2.72 Max: 4.23
Current: 1.13
During the past 13 years, Allergy Therapeutics's highest Current Ratio was 4.23. The lowest was 1.13. And the median was 2.72.
LSE:AGY's Current Ratio is ranked worse than 78.44% of 997
companies
in the Drug Manufacturers industry
Industry Median: 2
vs LSE:AGY: 1.13
Allergy Therapeutics (LSE:AGY) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Allergy Therapeutics Current Ratio Related Terms
Allergy Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Allergy Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:AGY vs ZTS, UTHR, VTRS: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allergy Therapeutics Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Allergy Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allergy Therapeutics (LSE:AGY) has a Current Ratio of 1.13 as of Dec. 2025. This is 58% below median its historical median of 2.72. Over the past decade, Allergy Therapeutics' Current Ratio has ranged from 1.13 to 4.23. According to the industry distribution chart, Allergy Therapeutics ranks #782 out of 997 companies in the Drug Manufacturers industry, placing it in the top 78.4%.
Is Allergy Therapeutics' Current Ratio too high?
Allergy Therapeutics' current Current Ratio of 1.13 is 58% below median its 10-year median of 2.72. Over the past 10 years, this metric has ranged from a low of 1.13 to a high of 4.23. The Drug Manufacturers industry median Current Ratio is 2.00. Allergy Therapeutics' value of 1.13 is 43.5% below this industry median. Based on the distribution chart, Allergy Therapeutics ranks #782 out of 997 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Allergy Therapeutics' Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allergy Therapeutics ranks #782 out of 997 companies for Current Ratio. This places Allergy Therapeutics in the lower half of its industry. The industry median Current Ratio is 2.00. Allergy Therapeutics' value of 1.13 is 43.5% below this benchmark. Historically, Allergy Therapeutics' own Current Ratio has ranged from 1.13 to 4.23 over the past decade. While the company's 10-year median is 2.72 vs. the industry median of 2.00, Allergy Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allergy Therapeutics's current Current Ratio of 1.13 is 43.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allergy Therapeutics's current Current Ratio is 1.13, which is 58% below median its own 10-year median of 2.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (LSE:AGY) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.03, compared to a current price of £0.06 — trading 110% above its estimated fair value. The current Current Ratio is 1.13, which is 58% below median its 10-year median of 2.72 and 43.5% below the Drug Manufacturers industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Allergy Therapeutics (LSE:AGY), the current Current Ratio is 1.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:AGY has been successfully added to your 